PD-1在外周血Treg细胞中的表达与不同病理、分期、治疗方式非霍奇金淋巴瘤患者预后相关性分析  

The Correlation Analysis Between the Expression of PD-1 in Peripheral Blood Treg Cells and the Prognosis of Non Hodgkin's Lymphoma Patients with Different Pathology,Staging and Treatment Methods

作　　者：祝壹青 胡海珍[1] 彭跃娇 黄丽云 张玉[1] ZHU Yiqing;HU Haizhen;PENG Yuejiao;HUANG Liyun;ZHANG Yu(Department of Hematology,the Second Affiliated Hospital of Nanchang University,Nanchang 330000,China)

机构地区：[1]南昌大学第二附属医院血液内科,南昌市330000

出　　处：《中国医药指南》2024年第30期25-28,共4页Guide of China Medicine

摘　　要：目的 探讨PD-1在外周血Treg细胞中的表达与不同病理、分期、治疗方式非霍奇金淋巴瘤患者预后的相关性。方法 选择2020年1月至2021年4月于我院接受治疗的非霍奇金淋巴瘤(NHL)患者共计74例,所有患者均经病理学组织检查确诊。统计所有患者淋巴瘤病理类型、临床分期以及治疗方式,测定患者程序性细胞死亡受体(PD-1)在患者外周血调节性T细胞(Treg)中的表达水平,并根据PD-1测定结果进行COX回归,分析患者预后情况。结果 (1)本研究74例患者分为:15例前驱淋巴性肿瘤(20.27%),21例惰性NHL(28.38%),19例侵袭性NHL(25.68%),19例成熟T细胞和NK细胞淋巴瘤(25.68%)。临床分期:Ⅰ期4例(5.41%),Ⅱ期23例(31.08%),Ⅲ期36例(48.65%),Ⅳ期11例(14.86%)。治疗方式:放疗16例(21.62%),联合化疗29例(39.19%),靶向药物治疗11例(14.86%),手术切除18例(24.32%)。(2)将侵袭性NHL作为对比因素,惰性NHL(P=0.000,HR=0.205)、前驱淋巴性肿瘤(P=0.013,HR=0.331)、成熟T细胞和NK细胞淋巴瘤(P=0.037,HR=0.329)的患者生存情况更好;将临床Ⅳ期作为对比因素,临床Ⅱ期(P=0.013,HR=0.252)、临床Ⅰ期(P=0.007,HR=0.104)的患者生存情况更好;将手术切除作为对比因素,靶向药物治疗(P=0.031,HR=1.279)的患者生存情况与手术切除类似。(3)测定患者外周血Treg细胞中的PD-1水平,结果显示:在患者不同病理分类、临床分期、治疗方式的分类下,PD-1水平均表现出了差异性(P <0.05),其中,侵袭性NHL、Ⅳ期以及联合化疗的情况下患者PD-1水平最高。结论 PD-1在不同病理类型、临床分期、治疗方式的NHL患者中表达存在差异;PD-1高水平表达的NHL患者预后较差。Objective To explore the correlation between the expression of PD-1 in peripheral blood Treg cells and the prognosis of non Hodgkin's lymphoma patients with different pathology,staging,and treatment methods.Methods A total of 74 patients with non Hodgkin's lymphoma(NHL)who received treatment in our hospital from January 2020 to April 2021 were selected,and all patients were confirmed by pathological tissue examination.Collect the pathological types,clinical stages,and treatment methods of lymphoma in all patients,measure the expression level of programmed cell death receptor(PD-1) in peripheral blood regulatory T cells(Treg),and perform COX regression based on the PD-1 measurement results to analyze the patient's prognosis.Results(1) In this study,74 patients were divided into 15 cases of prodromal lymphoid tumors(20.27%),21 cases of inert NHL(28.38%),19 cases of invasive NHL(25.68%),and 19 cases of mature T cell and NK cell lymphoma(25.68%).Clinical staging:Stage Ⅰ in 4 cases(5.41%),stage Ⅱ in 23 cases(31.08%),stage Ⅲ in 36 cases(48.65%),and stage Ⅳ in 11 cases(14.86%).Treatment methods:Radiotherapy in 16 cases(21.62%),combined chemotherapy in 29 cases(39.19%),targeted drug therapy in 11 cases(14.86%),and surgical resection in 18 cases(24.32%).(2) Using invasive NHL as a comparative factor,patients with inert NHL(P=0.000,HR=0.205),prodromal lymphoid tumors(P=0.013,HR=0.331),mature T cell and NK cell lymphoma(P=0.037,HR=0.329) had better survival outcomes;using clinical stage Ⅳ as a comparative factor,patients in clinical stage Ⅱ(P=0.013,HR=0.252) and clinical stage Ⅰ(P=0.007,HR=0.104) had better survival outcomes;the survival of patients treated with targeted drug therapy(P=0.031,HR=1.279) was similar to that of patients treated with surgical resection as a comparative factor.(3) The PD-1 levels in peripheral blood treg cells of patients were measured,and the results showed that there were differences in PD-1 levels among different pathological classifications,clinical stages,and treatment methods(

关 键 词：程序性细胞死亡受体 调节性T细胞 非霍奇金淋巴瘤 预后 

分 类 号：R733.1[医药卫生—肿瘤]